#1 Clinical Trials Search in Europe

R3R01

R3R01 is an investigational drug currently being studied in clinical trials for various kidney disorders. This article provides an overview of the ongoing research on R3R01, focusing on its potential benefits for patients with Alport Syndrome, Focal Segmental Glomerulosclerosis (FSGS), and Diabetic Kidney Disease. The trials aim to assess the safety, tolerability, and efficacy of R3R01 in improving kidney function and reducing protein excretion in urine.

Table of Contents

What is R3R01?

R3R01 is an investigational small molecule drug that is currently being studied for its potential to treat various kidney diseases[1]. It is designed to improve kidney function and reduce kidney damage by targeting specific processes within kidney cells[1]. As an investigational drug, R3R01 is still undergoing clinical trials to determine its safety and effectiveness in treating kidney-related conditions.

How Does R3R01 Work?

R3R01 works in two main ways:

  1. Decreasing fat levels in kidney cells: The drug is designed to reduce the amount of fat that accumulates in certain cells within the kidney. This fat accumulation, also known as lipotoxicity, is believed to play a role in kidney damage and disease progression[1].
  2. Increasing cholesterol efflux: R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer. This means it helps increase the movement of cholesterol out of kidney cells, which may help protect against kidney damage[2].

By targeting these processes, R3R01 aims to improve overall kidney function and slow down or prevent further kidney damage in patients with various kidney diseases.

What Conditions Does R3R01 Treat?

R3R01 is being studied for its potential to treat several kidney-related conditions:

  • Alport Syndrome (AS): A genetic disorder that affects the kidneys, eyes, and hearing[1].
  • Focal Segmental Glomerulosclerosis (FSGS): A type of kidney disease that causes scarring in parts of the kidney’s filtering units[1].
  • Diabetic Kidney Disease (DKD): A complication of diabetes that affects the kidneys[2].

These conditions are all characterized by damage to the kidneys and often result in the presence of protein in the urine, a condition known as proteinuria or albuminuria.

Current Clinical Trials

R3R01 is currently being evaluated in two main clinical trials:

  1. Study for Alport Syndrome and FSGS: This is a Phase 2, multi-center, open-label study assessing the safety, tolerability, efficacy, and pharmacokinetics of R3R01 in patients with Alport Syndrome and primary steroid-resistant FSGS[1].
  2. Study for Diabetic Kidney Disease: This is a double-blind, placebo-controlled study evaluating the effects of R3R01 on albuminuria levels in patients with diabetic kidney disease[2].

These trials aim to determine how well R3R01 works in reducing protein in the urine and improving overall kidney function in patients with these conditions.

Dosage and Administration

In the current clinical trials, R3R01 is being administered as follows:

  • Oral tablets of 200 mg taken twice daily[1][2].
  • The treatment period in these trials is typically 12 weeks (84 days)[1][2].

It’s important to note that as R3R01 is still an investigational drug, the optimal dosage and duration of treatment may change based on the results of these and future clinical trials.

Potential Benefits of R3R01

The clinical trials are investigating several potential benefits of R3R01:

  • Reduction in proteinuria: The primary goal is to decrease the amount of protein in the urine, which is a key indicator of kidney health[1][2].
  • Improved kidney function: Researchers are measuring changes in glomerular filtration rate (GFR), which indicates how well the kidneys are filtering waste from the blood[2].
  • Blood pressure control: The effect of R3R01 on blood pressure is being monitored, as high blood pressure can both cause and result from kidney disease[2].
  • Quality of life improvements: For both adult and pediatric patients, changes in quality of life are being assessed[1].

Safety and Monitoring

As with all clinical trials, the safety of R3R01 is being closely monitored. This includes:

  • Tracking the incidence of adverse events (side effects)[1].
  • Regular blood and urine tests to monitor kidney function and overall health[2].
  • Measuring the levels of R3R01 in the blood to understand how the body processes the drug (pharmacokinetics)[2].

It’s important to remember that as an investigational drug, the full safety profile of R3R01 is still being determined. Patients considering participating in clinical trials should discuss the potential risks and benefits with their healthcare providers.

Aspect Details
Drug Name R3R01
Mechanism of Action ABCA1 inducer, decreases fat levels in kidney cells
Conditions Studied Alport Syndrome, Focal Segmental Glomerulosclerosis, Diabetic Kidney Disease
Administration Oral tablets, 200 mg twice daily
Primary Outcomes Changes in proteinuria, safety, and tolerability
Secondary Outcomes Kidney function, blood pressure, quality of life
Study Designs Open-label and double-blind, placebo-controlled trials
Treatment Duration 12-24 weeks
Patient Age Range 12 years and older (varies by study)

FAQ

  • What is R3R01 and how does it work? R3R01 is an investigational small molecule designed to decrease fat levels in certain kidney cells. It works as an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the removal of cholesterol from the cells in the kidney. This mechanism may help improve kidney function and reduce damage.
  • What conditions are being studied with R3R01? R3R01 is being studied for several kidney disorders, including Alport Syndrome, Focal Segmental Glomerulosclerosis (FSGS), and Diabetic Kidney Disease. These conditions are characterized by protein loss in the urine and progressive kidney damage.
  • How is R3R01 administered in the clinical trials? In the clinical trials, R3R01 is administered orally as 200 mg tablets twice daily. The treatment period in the studies ranges from 12 to 24 weeks, depending on the specific trial design.
  • What are the main outcomes being measured in these trials? The main outcomes being measured include changes in protein levels in urine (proteinuria), kidney function (measured by glomerular filtration rate), blood pressure, and quality of life. The trials also assess the safety and tolerability of R3R01 by monitoring adverse events.
  • Who can participate in these clinical trials? The eligibility criteria vary depending on the specific trial. Generally, patients aged 12 and older with Alport Syndrome or FSGS can participate in one study, while adults (18 years and older) with type 2 diabetes and kidney disease are eligible for another study. Specific medical criteria, such as protein levels in urine and kidney function, are also considered for enrollment.

Ongoing Clinical Trials on R3R01

  • Study on the Effects of R3R01 on Reducing Protein in Urine for Patients with Diabetic Kidney Disease

    Recruiting

    2 1 1
    Investigated drugs:
    Denmark

  • Study on R3R01 for Patients with Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany The Netherlands

Glossary

  • Alport Syndrome: A genetic condition that affects the kidneys, eyes, and hearing. It is characterized by progressive kidney disease and loss of kidney function.
  • Focal Segmental Glomerulosclerosis (FSGS): A type of kidney disease that affects the glomeruli (tiny filtering units in the kidneys) and causes scarring. It can lead to kidney failure if left untreated.
  • Diabetic Kidney Disease: A complication of diabetes that affects the kidneys, leading to damage of the kidney's filtering system and potentially causing kidney failure.
  • Proteinuria: The presence of excess protein in the urine, which can be a sign of kidney damage or disease.
  • Glomerular Filtration Rate (GFR): A measure of how well the kidneys are filtering waste from the blood. It is used to assess kidney function and stage kidney disease.
  • ACE/ARB Inhibition: Medications that help lower blood pressure and protect kidney function in patients with certain kidney diseases.
  • Albuminuria: The presence of albumin (a type of protein) in the urine, which can indicate kidney damage.
  • ABCA1 Inducer: A substance that increases the activity of the ABCA1 transporter, which helps remove cholesterol from cells.
  • Lipotoxicity: The harmful effects of excess fat accumulation in cells or tissues, which can contribute to organ damage.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References